EFSA and GB-Authorised Health Claims for Omega-3

You have probably seen them on the back of a fish oil bottle in Boots or scrolled past them on a product page: "supports heart health," "maintains brain function." They sound like marketing. Some of them are. But a specific subset of omega-3 health claims has been evaluated by the European Food Safety Authority, found to be supported by the evidence, and formally authorised under EU law. These are the only claims that survived independent scientific review.

What EFSA Authorisation Actually Means

An EFSA-authorised health claim is not a marketing phrase. It is a specific statement that has been through formal scientific assessment by the European Food Safety Authority, found to have sufficient supporting evidence, and approved for use under Commission Regulation (EU) No 432/2012. We described how this fits into our broader evidence framework in our claims and evidence matrix.

The authorisation comes with conditions, and the conditions are the part most packaging conveniently shrinks to fine print. Each claim specifies the nutrient, the health relationship, the minimum daily intake required, and the target population. A company cannot use the authorised wording without meeting the intake threshold. A product delivering 50mg of DHA per dose cannot legally carry a claim that requires 250mg daily.

In the UK, these claims remain applicable under retained EU law following Brexit. The GB Nutrition and Health Claims Register mirrors the EU register, though the regulatory pathway for new claims now runs through the UK's own assessment process.

Authorised Health Claims for EPA and DHA

The following claims are authorised under EU 432/2012 and applicable in GB. The exact intake requirement is included for each, because a claim without its threshold is incomplete.

Standard-Dose Authorised Claims for Omega-3

Heart function: "EPA and DHA contribute to the normal function of the heart." Requirement: a minimum of 250mg combined EPA and DHA daily.

Brain function: "DHA contributes to the maintenance of normal brain function." Requirement: a minimum of 250mg DHA daily.

Normal vision: "DHA contributes to the maintenance of normal vision." Requirement: a minimum of 250mg DHA daily.

DHA Claims for Maternal and Infant Nutrition

Maternal intake of DHA is linked to two authorised claims covering normal eye development and normal brain development of the foetus and breastfed infants. Both require 200mg DHA daily on top of the recommended 250mg EPA and DHA for adults. Most marketing presents only the 200mg figure. The actual requirement is 200mg DHA plus 250mg combined EPA and DHA, totalling at least 450mg daily.

Higher-Dose Claims for Blood Pressure and Triglycerides

Maintenance of normal blood pressure requires a combined intake of at least 3g EPA and DHA daily. The blood triglyceride claim requires at least 2g combined daily. A separate triglyceride claim for DHA alone also sets a 2g daily threshold.

Note the dose thresholds. A standard omega-3 supplement delivering 250 to 500mg per day qualifies for the heart, brain, and vision claims. The blood pressure and triglyceride claims require doses that most single-capsule products do not reach. If you see a standard-dose supplement carrying those higher-dose claims, the intake threshold is not being met.

Check your own label and do the arithmetic before you assume the claim applies to what you are taking.

Common Omega-3 Claims That Are Not EFSA-Authorised

This is where the gap between what you read on the shelf and what a regulator would approve becomes visible. When we first sat down and mapped competitor labels against the EFSA register, we were struck by how routine the overstep is. The following claims appear frequently on omega-3 products. None are authorised:

"Reduces inflammation" or "anti-inflammatory." EPA is involved in eicosanoid pathways related to the inflammatory response, and that is established biochemistry. But no authorised claim permits this as a consumer-facing benefit.

"Boosts the immune system." No authorised immune-function claim exists for EPA or DHA at any dose.

"Improves cognitive performance" or "enhances brain function." The authorised wording refers to maintenance of normal brain function, not improvement or enhancement. The distinction matters when you are reading product labels.

"Prevents heart disease." The authorised wording refers to the normal function of the heart. No disease-risk-reduction claim is authorised at the standard intake level.

"Essential for joint health." No authorised joint-health claim exists for EPA or DHA despite how commonly you will find this on packaging.

How to Check Whether a Claim on Your Omega-3 Supplement Is Authorised

The EU Register of Nutrition and Health Claims is publicly searchable. Look up the specific nutrient and the claimed health relationship. If the exact wording appears with its conditions, the claim is authorised. If the wording on the product differs from the register, or if no entry exists, the claim has no regulatory backing.

When we mapped the claims on competing omega-3 products against the register, the majority included at least one statement that is not authorised. The most common was the inflammation claim, followed by immune support. Both sound scientific. Neither has passed EFSA's evidence threshold. We use only authorised wording on our products and cite the regulation and condition alongside each claim. Our broader approach to evidence evaluation is described separately.

EFSA Authorised Claims for Omega-3 FAQs

What does "contributes to normal function" mean in EFSA language?

It means the nutrient supports a bodily process that is already working as it should. It does not mean it improves, enhances, or restores that process. The conservative phrasing reflects the regulator's policy of approving only what the data can defend at a stated daily amount.

Why does the 250mg threshold matter?

Because the approved wording is conditional on reaching that daily amount. A capsule delivering 100mg cannot legally carry the cardiac benefit statement. Before relying on an EFSA-backed benefit, verify that your daily serving meets the gram figure printed in the regulation.

Can a supplement claim to reduce inflammation if it contains EPA?

No. EPA participates in eicosanoid signalling pathways linked to the inflammatory response, and that biochemistry is well documented. But the regulator has not approved any consumer-facing statement using the word "inflammation" for long-chain fatty acids at any gram level. The science exists; the approved wording does not.

Do UK regulations differ from EU regulations on omega-3 claims?

Not for existing approvals. The GB register retains the same list that was in force before Brexit. The divergence is procedural: any future application for a new approved statement goes through a UK-specific review body rather than EFSA. For now, the catalogue of permitted wording is identical on both sides.

What should I do if I see an unauthorised claim on an omega-3 product?

Read it as a quality signal. Either the company made a regulatory mistake or it chose wording that sounds credible but lacks formal backing. Both possibilities tell you how carefully the brand separates peer-reviewed findings from promotional language. A seller that blurs the line on one statement may blur it on others.

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Consult your GP or a qualified healthcare professional before starting any supplement.

Methodology and Disclosure

All authorised claims cite Commission Regulation (EU) No 432/2012. The nutrition and health claims framework cites Regulation (EC) No 1924/2006. EFSA scientific opinion on EPA and DHA cites EFSA Journal 2010. UK regulatory position reflects retained EU law as of the date of publication. Competitor claim mapping reflects our own market review.

Vendor disclosure: Phytality manufactures omega-3 supplements and uses only EFSA-authorised claims on its products. The competitor claim mapping reveals widespread use of unauthorised wording across the omega-3 market. Our interest in regulatory compliance being understood as a quality marker is both editorial and commercial.